Cory S. Anderson
Executive Vice President & General Manager of GreenbrookMr. Cory S. Anderson has been the Executive Vice President and General Manager of Greenbrook at Neuronetics, Inc. since July 01, 2026. He served as Senior Vice President & Chief Technology Officer at Neuronetics, Inc. from 2025 until July 01, 2026 and was it's Senior Vice President of R&D and Clinical since February 2023 until 2025 He was a Principal at Accuitive Medical Ventures, LLC. He was an associate at the firm. He focused on new business development at the firms and also early-stage investing in the medical device sector. He focused on identifying investment opportunities, conducting due diligence, supporting portfolio companies and financial analysis and forecasting. He is a VP Clinical Marketing and Business Development for Sebacia. He was Vice President at The Innovation Factory, LLC. He was the Program Manager for AqueSys from its inception through its transition out of TIF. Following the transition to permanent management, he remained involved with the company as a Board observer until its exit to Allergan in 2015. For AqueSys, he managed the transformation of an academic invention into a product and through its initial clinical studies internationally. He was Associate at The Innovation Factory. Prior to joining the firm, Mr. Anderson was the Director of Product Development at The Innovation Factory LLC. In that role, he served as the Program Manager for NeoVista and AqueSys, through their Phase I clinical studies. Prior to this, Mr. Anderson worked in research, development and marketing at Novoste Corporation as Product Manager, where he focused on new growth opportunities in addition to holding various positions within R&D and led several product and market development efforts for a variety of diseases and conditions including: atrial fibrillation, peripheral vascular disease, chronic total occlusions and Barrett’s Esophagus. Mr. Anderson currently serves as a Board Observer for AqueSys. He currently has two pending patent applications and has authored two peer-reviewed journal articles along with one textbook chapter. He is currently a Board Observer for Myoscience. He has experience in conducting Investor due diligence in multiple disease states across multiple technologies. He has successfully raised equity and debt financing for portfolio companies. He has been responsible for vetting new investment opportunities for AMV and building business plans for new TIF companies. Operationally, he has experience in new product development of medical technologies, designing and conducting clinical studies worldwide, commercially launching products in Europe, developing regulatory strategies and managing intellectual property portfolios. Mr. Anderson earned an M.B.A. from Emory University. He holds an M.S. in Biomedical Engineering with a thesis in Cardiac Electrophysiology and a B.S. in Biomedical Engineering with honors from Tulane University.
Positions
- Company NameNeuronetics, Inc.Stock CodeSTIMPositionExecutive Vice President & General Manager of GreenbrookColleagues
- DLDaniel L. ReuversCEO, President & Director
- RARobert A. CascellaIndependent Chairman of the Board
- NNNir NaorExecutive VP, CFO, Corporate Secretary, Principal Financial and Accounting Officer & Treasurer
- RGRobert GreeneSenior Vice President of Sales
- GPGlenn P. MuirIndependent Director
- SLSheryl L. ConleyIndependent Director
- MRMegan R. RosengartenIndependent Director
